Life Sciences Acceleration

In life sciences, IP value is often determined by what gets proven, how it gets proven, and whether the development plan supports a credible partnering narrative. Too often, legal strategy, scientific development, and commercialization planning are built in separate lanes. MIM helps align them.

Within the MIM legal engagement, we shape portfolio strategy, prosecution posture, transactions, and legal risk positioning around value-driving scientific milestones. Where appropriate, clients may separately engage Miletus Biotechnology for non-legal scientific development and commercialization support.

Who This Is For

  • CEOs and founders who need development milestones that increase IP leverage and partnering credibility.

  • General counsel who need a governable plan with a clean privilege boundary.

  • Investors who need a thesis that connects IP, data, commercialization, and valuation.

  • Chief IP counsel who need IP strategy matched to what the science can support and what the market will reward.

Common Starting Triggers

  • We need data that strengthens our IP position and partnering story.

  • Our development plan and IP plan are not aligned.

  • We are approaching partnering or financing and need a coherent narrative.

  • We want to avoid wasting spend on filings that will not hold up in diligence.

Outcomes You Can Expect

  • A science-to-asset plan that ties data milestones to claim value.

  • A portfolio posture built for partnering and diligence.

  • Reduced risk of filing too early or too late.

  • A more coherent narrative across IP, technical story, and commercialization path.

One Coordinated Plan, Two Clean Roles

  • MIM = legal counsel: Portfolio strategy, prosecution, transactions, and legal risk posture are delivered within the MIM legal engagement and protected by attorney-client privilege.

  • MBT = non-legal advisory / execution: Scientific development and commercialization support may be delivered through a separate engagement with MBT where useful.

  • One coordinated roadmap: The roadmap is aligned, but roles and privilege remain clean.

In life sciences, claim value and development value should not be built in separate lanes.

Discuss a Coordinated Roadmap